Increased antiparkinson efficacy of the combined administration of VEGF- and GDNF-loaded nanospheres in a partial lesion model of Parkinson’s disease
Enara Herrán,1,2 Catalina Requejo,3 Jose Angel Ruiz-Ortega,4 Asier Aristieta,4 Manoli Igartua,1,2 Harkaitz Bengoetxea,3 Luisa Ugedo,4 Jose Luis Pedraz,1,2 Jose Vicente Lafuente,3 Rosa Maria Hernández1,2 1NanoBioCel Group, Laboratory of Pharmaceutics, University of the Basque...
Guardado en:
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2014
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/a465628eec9d4a84ab7a94e9e046e0d8 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:a465628eec9d4a84ab7a94e9e046e0d8 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:a465628eec9d4a84ab7a94e9e046e0d82021-12-02T00:37:18ZIncreased antiparkinson efficacy of the combined administration of VEGF- and GDNF-loaded nanospheres in a partial lesion model of Parkinson’s disease1178-2013https://doaj.org/article/a465628eec9d4a84ab7a94e9e046e0d82014-05-01T00:00:00Zhttp://www.dovepress.com/increased-antiparkinson-efficacy-of-the-combined-administration-of-veg-a17018https://doaj.org/toc/1178-2013 Enara Herrán,1,2 Catalina Requejo,3 Jose Angel Ruiz-Ortega,4 Asier Aristieta,4 Manoli Igartua,1,2 Harkaitz Bengoetxea,3 Luisa Ugedo,4 Jose Luis Pedraz,1,2 Jose Vicente Lafuente,3 Rosa Maria Hernández1,2 1NanoBioCel Group, Laboratory of Pharmaceutics, University of the Basque Country (UPV/EHU), School of Pharmacy, Vitoria, Spain; 2Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Vitoria, Spain; 3LaNCE, Department of Neurosciences, University of the Basque Country (UPV/EHU), Leioa, Spain; 4Department of Pharmacology, University of the Basque Country (UPV/EHU), Leioa, Spain Abstract: Current research efforts are focused on the application of growth factors, such as glial cell line-derived neurotrophic factor (GDNF) and vascular endothelial growth factor (VEGF), as neuroregenerative approaches that will prevent the neurodegenerative process in Parkinson’s disease. Continuing a previous work published by our research group, and with the aim to overcome different limitations related to growth factor administration, VEGF and GDNF were encapsulated in poly(lactic-co-glycolic acid) nanospheres (NS). This strategy facilitates the combined administration of the VEGF and GDNF into the brain of 6-hydroxydopamine (6-OHDA) partially lesioned rats, resulting in a continuous and simultaneous drug release. The NS particle size was about 200 nm and the simultaneous addition of VEGF NS and GDNF NS resulted in significant protection of the PC-12 cell line against 6-OHDA in vitro. Once the poly(lactic-co-glycolic acid) NS were implanted into the striatum of 6-OHDA partially lesioned rats, the amphetamine rotation behavior test was carried out over 10 weeks, in order to check for in vivo efficacy. The results showed that VEGF NS and GDNF NS significantly decreased the ­number of amphetamine-induced rotations at the end of the study. In addition, tyrosine hydroxylase immunohistochemical analysis in the striatum and the external substantia nigra confirmed a significant enhancement of neurons in the VEGF NS and GDNF NS treatment group. The synergistic effect of VEGF NS and GDNF NS allows for a reduction of the dose by half, and may be a valuable neurogenerative/neuroreparative approach for treating Parkinson’s disease. Keywords: nanoparticles, PLGA, 6-OHDA, neuroregeneration, neurotrophic factors, tyrosine hydroxylaseHerrán ERequejo CRuiz-Ortega JAAristieta AIgartua MBengoetxea HUgedo LPedraz JLLafuente JVHernández RMDove Medical PressarticleMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol 2014, Iss Issue 1, Pp 2677-2687 (2014) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine (General) R5-920 |
| spellingShingle |
Medicine (General) R5-920 Herrán E Requejo C Ruiz-Ortega JA Aristieta A Igartua M Bengoetxea H Ugedo L Pedraz JL Lafuente JV Hernández RM Increased antiparkinson efficacy of the combined administration of VEGF- and GDNF-loaded nanospheres in a partial lesion model of Parkinson’s disease |
| description |
Enara Herrán,1,2 Catalina Requejo,3 Jose Angel Ruiz-Ortega,4 Asier Aristieta,4 Manoli Igartua,1,2 Harkaitz Bengoetxea,3 Luisa Ugedo,4 Jose Luis Pedraz,1,2 Jose Vicente Lafuente,3 Rosa Maria Hernández1,2 1NanoBioCel Group, Laboratory of Pharmaceutics, University of the Basque Country (UPV/EHU), School of Pharmacy, Vitoria, Spain; 2Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Vitoria, Spain; 3LaNCE, Department of Neurosciences, University of the Basque Country (UPV/EHU), Leioa, Spain; 4Department of Pharmacology, University of the Basque Country (UPV/EHU), Leioa, Spain Abstract: Current research efforts are focused on the application of growth factors, such as glial cell line-derived neurotrophic factor (GDNF) and vascular endothelial growth factor (VEGF), as neuroregenerative approaches that will prevent the neurodegenerative process in Parkinson’s disease. Continuing a previous work published by our research group, and with the aim to overcome different limitations related to growth factor administration, VEGF and GDNF were encapsulated in poly(lactic-co-glycolic acid) nanospheres (NS). This strategy facilitates the combined administration of the VEGF and GDNF into the brain of 6-hydroxydopamine (6-OHDA) partially lesioned rats, resulting in a continuous and simultaneous drug release. The NS particle size was about 200 nm and the simultaneous addition of VEGF NS and GDNF NS resulted in significant protection of the PC-12 cell line against 6-OHDA in vitro. Once the poly(lactic-co-glycolic acid) NS were implanted into the striatum of 6-OHDA partially lesioned rats, the amphetamine rotation behavior test was carried out over 10 weeks, in order to check for in vivo efficacy. The results showed that VEGF NS and GDNF NS significantly decreased the ­number of amphetamine-induced rotations at the end of the study. In addition, tyrosine hydroxylase immunohistochemical analysis in the striatum and the external substantia nigra confirmed a significant enhancement of neurons in the VEGF NS and GDNF NS treatment group. The synergistic effect of VEGF NS and GDNF NS allows for a reduction of the dose by half, and may be a valuable neurogenerative/neuroreparative approach for treating Parkinson’s disease. Keywords: nanoparticles, PLGA, 6-OHDA, neuroregeneration, neurotrophic factors, tyrosine hydroxylase |
| format |
article |
| author |
Herrán E Requejo C Ruiz-Ortega JA Aristieta A Igartua M Bengoetxea H Ugedo L Pedraz JL Lafuente JV Hernández RM |
| author_facet |
Herrán E Requejo C Ruiz-Ortega JA Aristieta A Igartua M Bengoetxea H Ugedo L Pedraz JL Lafuente JV Hernández RM |
| author_sort |
Herrán E |
| title |
Increased antiparkinson efficacy of the combined administration of VEGF- and GDNF-loaded nanospheres in a partial lesion model of Parkinson’s disease |
| title_short |
Increased antiparkinson efficacy of the combined administration of VEGF- and GDNF-loaded nanospheres in a partial lesion model of Parkinson’s disease |
| title_full |
Increased antiparkinson efficacy of the combined administration of VEGF- and GDNF-loaded nanospheres in a partial lesion model of Parkinson’s disease |
| title_fullStr |
Increased antiparkinson efficacy of the combined administration of VEGF- and GDNF-loaded nanospheres in a partial lesion model of Parkinson’s disease |
| title_full_unstemmed |
Increased antiparkinson efficacy of the combined administration of VEGF- and GDNF-loaded nanospheres in a partial lesion model of Parkinson’s disease |
| title_sort |
increased antiparkinson efficacy of the combined administration of vegf- and gdnf-loaded nanospheres in a partial lesion model of parkinson’s disease |
| publisher |
Dove Medical Press |
| publishDate |
2014 |
| url |
https://doaj.org/article/a465628eec9d4a84ab7a94e9e046e0d8 |
| work_keys_str_mv |
AT herraacutene increasedantiparkinsonefficacyofthecombinedadministrationofvegfandgdnfloadednanospheresinapartiallesionmodelofparkinsonrsquosdisease AT requejoc increasedantiparkinsonefficacyofthecombinedadministrationofvegfandgdnfloadednanospheresinapartiallesionmodelofparkinsonrsquosdisease AT ruizortegaja increasedantiparkinsonefficacyofthecombinedadministrationofvegfandgdnfloadednanospheresinapartiallesionmodelofparkinsonrsquosdisease AT aristietaa increasedantiparkinsonefficacyofthecombinedadministrationofvegfandgdnfloadednanospheresinapartiallesionmodelofparkinsonrsquosdisease AT igartuam increasedantiparkinsonefficacyofthecombinedadministrationofvegfandgdnfloadednanospheresinapartiallesionmodelofparkinsonrsquosdisease AT bengoetxeah increasedantiparkinsonefficacyofthecombinedadministrationofvegfandgdnfloadednanospheresinapartiallesionmodelofparkinsonrsquosdisease AT ugedol increasedantiparkinsonefficacyofthecombinedadministrationofvegfandgdnfloadednanospheresinapartiallesionmodelofparkinsonrsquosdisease AT pedrazjl increasedantiparkinsonefficacyofthecombinedadministrationofvegfandgdnfloadednanospheresinapartiallesionmodelofparkinsonrsquosdisease AT lafuentejv increasedantiparkinsonefficacyofthecombinedadministrationofvegfandgdnfloadednanospheresinapartiallesionmodelofparkinsonrsquosdisease AT hernaacutendezrm increasedantiparkinsonefficacyofthecombinedadministrationofvegfandgdnfloadednanospheresinapartiallesionmodelofparkinsonrsquosdisease |
| _version_ |
1718403637259010048 |